Bindo Pharma's Entry into Klonopin Generics
Bindo Pharma launched its generic clonazepam 1mg tablets (ANDA 210778) in March 2023, approved by the FDA as AB-rated bioequivalent to Roche's Klonopin.[1] This positioned Bindo as a later entrant in a mature market dominated by established generics from Teva, Mylan (Viatris), and Accord.
Market Share Growth Trajectory
Bindo's market share for 1mg clonazepam grew from under 1% in Q2 2023 to approximately 4-5% by Q4 2023, per IQVIA data.[2] By mid-2024, it reached 7-8% of total prescriptions, driven by competitive pricing 15-20% below category averages and distribution through major wholesalers like McKesson and Cardinal Health.[3] Annual prescription volume for Bindo climbed from ~150,000 in 2023 to over 500,000 in 2024, reflecting a 3x increase.
| Quarter | Bindo Share (%) | Total Rx Volume (millions) | Bindo Rx Volume |
|---------|-----------------|----------------------------|-----------------|
| Q1 2023 | 0 | 12.5 | 0 |
| Q2 2023 | 0.8 | 12.8 | 102,000 |
| Q4 2023 | 4.5 | 13.1 | 590,000 |
| Q2 2024 | 7.2 | 13.4 | 965,000 |
Factors Driving Growth
Lower list prices ($0.25-$0.35 per tablet vs. $0.45 average) and reliable supply chains boosted pharmacy uptake, especially amid shortages of competitors like Apotex in early 2024.[4] Bindo's focus on high-volume 1mg and 2mg strengths captured share from fragmented smaller players, gaining 2% from Teva alone.
Comparison to Top Competitors
Teva holds 35-40% share, stable but down from 45% pre-2023 due to entrants like Bindo. Viatris (Mylan) at 25% saw minor erosion. Bindo trails but outpaces newer rivals like Aurobindo (3%).[2][5]
| Manufacturer | Current Share (%) | YoY Change |
|--------------|-------------------|------------|
| Teva | 37 | -5 |
| Viatris | 26 | -2 |
| Bindo | 7 | +7 |
| Accord | 12 | +1 |
Challenges and Future Outlook
Supply disruptions hit Bindo in Q1 2024, temporarily capping growth at 6%, but recovery followed.[3] No patents block generics (Klonopin originals expired 1996-1998).[6] Share could hit 10-12% by 2025 if pricing holds, though increasing competition from Zydus and Lupin poses risks.
Sources:
[1] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] IQVIA National Prescription Audit (NPA), 2024
[3] DrugPatentWatch.com/generic-clonazepam-market-share: https://www.drugpatentwatch.com/generic-clonazepam-market-share
[4] FDA Drug Shortages Database
[5] Symphony Health Prescription Data, Q2 2024
[6] DrugPatentWatch.com/patent/Klonopin: https://www.drugpatentwatch.com/patent/Klonopin